The nice people
at Transfusion News sent their update today. Again tranexamic acid appears. And
the article on alloimmunization was thought-provoking. Why do some people
create antibodies after a single transfusion and others have (literally)
gallons and create none?
Long-term Survival of Severe Trauma Patients Treated with Tranexamic Acid  | | June 21, 2023 | | Globally,
trauma is the leading cause of death for young people. In 2011, the
World Health Organization added tranexamic acid to the Model List of
Essential Medicines for the treatment of trauma based on randomized
trial data showing that tranexamic acid reduces mortality of
hemorrhaging trauma patients. [Read More] |
|
 | Hemagglutination
methods have been used over a century to determine blood group
phenotypes. Serology cannot be used in some situations, leading
laboratories to use molecular assays to predict red blood cell (RBC)
phenotypes. Sometimes the predicted phenotype does not fit with the
patient’s known antibodies or serological phenotype. These
phenotype/genotype discrepancies can lead to confusion for laboratory
and clinical staff. This can cause anxiety, delays in patient care, or
even incorrect conclusions and inappropriate clinical advice and patient
care.
Shane Grimsley
(DipRCPath) will explore some common discrepancies, detailing their
causes and how to safely investigate them. This information will provide
clues for resolving these issues and ensuring timely and accurate
patient care.
Join us on June 27th and 30th by registering for this webinar.
[Register Now]
PACE Eligible for 1.5 contact hours
 |
|
 | | June 14, 2023 | | RBC
alloimmunization from transfusions or pregnancy can be life
threatening. Currently, scientists have identified 43 polymorphic RBC
surface antigen systems, and some are more immunogenic than others.
Furthermore, there is a poor understanding of why most patients do not
develop alloantibodies and why others respond to one or several
antigens. [Read More] |
|
No comments:
Post a Comment